Status:
UNKNOWN
Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18-80 years
Brief Summary
The aim of the present study is to investigate the effects of evolocumab in addition to statin therapy on platelet reactivity in patients with acute coronary syndrome (ACS) while on Ticagrelor and Asp...
Detailed Description
Ticagrelor is a commercially available antiplatelet adenosine diphosphate (ADP) antagonists. They exert their antiplatelet effects by binding to P2Y12 receptors on the platelet surface. Ticagrelor is ...
Eligibility Criteria
Inclusion
- Patients were diagnosed as acute coronary disease
- On therapy with Ticagrelor(90mg bid) and Aspirin(100mg qd), for at least 5 days.
- Fasting LDL-cholesterol ≥70 mg/dL or a non-high-density lipoprotein cholesterol (HDL-C) of ≥100 mg/dL after ≥4 weeks of optimized stable lipid-lowering therapy with maximally tolerated dose of statin.
- Have not used Evolocumab in 30 days.
Exclusion
- On treatment with any oral anticoagulant.
- On treatment with any antiplatelet agent other than Aspirin and Ticagrelor in the past 5 days.
- Creatinine clearance \<30 mL/minute.
- Known severe hepatic impairment.
- History of a serious hypersensitivity reaction to evolocumab
- Hemodynamic instability
- Pregnant and breastfeeding women.
Key Trial Info
Start Date :
December 23 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05418166
Start Date
December 23 2021
End Date
September 1 2022
Last Update
June 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the first affiliated hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150000